Characterizing comorbidity in dialysis patients: Principles of measurement and applications in risk adjustment and patient care

Peritoneal Dialysis International

Volumn 25, Issue 4, 2005, Pages 320-332

  Miskulin, Dana ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Case mix adjustment; Case mix severity; Quality of care; Questionnaires; Survival analysis

Indexed keywords

ACCURACY; CASE MIX; CLINICAL TRIAL; COMORBIDITY; DISEASE SEVERITY; HEALTH CARE COST; HEALTH CARE QUALITY; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; INFLAMMATION; INFORMATION PROCESSING; KIDNEY FAILURE; MEDICAL RECORD; MORTALITY; NUTRITIONAL STATUS; PATIENT CARE; PERITONEAL DIALYSIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SELF REPORT;

EID: 23744468016     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080502500403     Document Type: Review

References (83)

1. Sarnak M, Levey A. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000; 35(4 Suppl 11):S117-31.
2. Foley R, Parfrey PS, Sarnak MJ. The clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(5 Suppl 3):S112-19.
3. United States Renal Data System. Excerpts from the USRDS 2004 annual renal data report. Am J Kidney Dis 2005; 45(1 Pt 2):1-280.
4. Xue J, Ma J, Louis T, Collins A. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001; 12:2753-8.
5. Muntner P, Coresh J, Powe N, Klag M. The contribution of increased diabetes prevalence and improved myocardial infarction and stroke survival to the increase in treated end-stage renal disease. J Am Soc Nephrol 2003; 14: 1568-77.
6. Hsu C-Y, Vittinghoff E, Lin F, Shlipak MG. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 2004; 141:95-101.
7. Port F. The end-stage renal disease program: trends over the past 18 years. Am J Kidney Dis 1992; 20:3-7.
8. Mailloux LU, Napolitano B, Alessandro G, Bellucci G, Mossey RT, Vernace MA, et al. The impact of co-morbid risk factors at the start of dialysis upon the survival of ESRD patients. ASAIO J 1996; 42:164-9.
9. Hylander B, Lundblad H, Kjellstrand C. Changing patient characteristics in chronic hemodialysis. Scand J Urol Nephrol 1991; 25:59-63.
10. Collins AJ, Hanson G, Umen A, Kjellstrand C, Keshaviah P. Changing risk factor demographics in ESRD patients entering hemodialysis and the impact on long-term mortality. Am J Kidney Dis 1990; 15:422-32.
11. Iezzoni L. Risk Adjustment for Measuring Health Outcomes. 2nd ed. Ann Arbor, MI: Health Administration Press; 1997.
12. Greenfield S, Aronow HU, Elashoff RM, Watanabe D. Flaws in mortality data: the hazards of ignoring comorbid disease. JAMA 1988; 260:2253-5.
13. Stack A. Determinants of modality selection among incident US dialysis patients: results from a national study. J Am Soc Nephrol 2002; 13:1279-87.
14. Miskulin DC, Meyer KB, Athienites NV, Martin AA, Marsh JV, Fink NF, et al. Comorbidity and other factors associated with modality selection in incident dialysis patients: the CHOICE Study. Am J Kidney Dis 2002; 39:324-36.
15. Collins A, Weinhandl E, Snyder J, Shu-Cheng C, Gilberston D. Comparison and survival of hemodialysis and peritoneal dialysis in the elderly. Semin Dial 2002; 15:98-102.
16. Greenfield S, Sullivan L, Silliman RA, Dukes K, Kaplan SH. Principles and practice of case-mix adjustment: applications to end-stage renal disease. Am J Kidney Dis 1994; 24:298-307.
17. Wolfe R, Gaylin D, Port F, Held P, Wood C. Using USRDS generated mortality tables to compare local ESRD mortality rates to national rates. Kidney Int 1992; 42:991-6.
18. Khan I, Campbell M, Cantarovich D, Catto G, Delcroix D, Edward N, et al. Comparing outcomes in renal replacement therapy: how should we correct for case mix? [Published erratum appears in Am J Kidney Dis 1998; 31:900]. Am J Kidney Dis 1998; 31:473-8.
19. Athienites NV, Miskulin DC, Fernandez GF, Bunnapradist S, Simon G, Landa M, et al. Comorbidity assessment in hemodialysis and peritoneal dialysis using the Index of Coexistent Disease (ICED). Semin Dial 2000; 13:320-6.
20. Sehgal A, Grey S, DeOreo P, Whitehouse P. Prevalence, recognition, and implications of mental impairment among hemodialysis patients. Am J Kidney Dis 1997; 30:41-9.
21. Kurella M, Chertow G, Luan J, Yaffe K. Cognitive impairment in chronic kidney disease. J Am Geriatr Soc 2004; 52:1863-9.
22. Merkin SS, Longenecker JC, Fink NE, Levey AS, Powe NR. Comparison of patients reports of comorbid disease with the medical record [Abstract]. J Am Soc Nephrol 2000; 11: 157A.
23. United States Renal Data System. USRDS 1991 annual data report: comorbid conditions and correlations with mortality risk among 3,399 incident hemodialysis patients. Am J Kidney Dis 1992; 20:32-8.
24. Longenecker JC, Klag MJ, Coresh J, Levey AS, Martin AA, Fink NE, et al. Validation of comorbid conditions on the end-stage renal disease medical evidence report: the CHOICE Study. J Am Soc Nephrol 2000; 11:520-9.
25. Khan I, Graeme R, Edward N, Fleming L, Henderson I, MacLeod A. Influence of coexisting disease on survival on renal-replacement therapy. Lancet 1993; 341:415-18.
26. Nicolucci A, Cubasso D, Labbrozzi D, Mari E, Imicciatore P, Procaccini DA, et al. Effect of coexistent diseases on survival of patients undergoing dialysis. ASAIO J 1995; 41: M291-M295.
27. Miskulin D, Martin A, Brown R, Levey A. Development and validation of a dialysis-specific comorbidity index [Abstract]. J Am Soc Nephrol 2002; 13:613A.
28. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-83.
29. Fried L, Bernardini J, Piraino B. Charlson Comorbidity Index as a predictor of outcomes in incident peritoneal dialysis patients. Am J Kidney Dis 2001; 37:337-42.
30. Hemmelgarn BR, Manns BJ, Quan H, Ghali WA. Adapting the Charlson Comorbidity Index for use in patients with ESRD. Am J Kidney Dis 2003; 42:125-32.
31. van Manen J, Korevaar J, Dekker F, Boeschoten E, Bossuyt P, Krediet R. How to adjust for comorbidity in survival studies in ESRD patients: a comparison of different indices. Am J Kidney Dis 2002; 40:82-9.
32. Beddhu S, Bruns FJ, Saul M, Seddon P, Zeidel ML. A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J Med 2000; 108:609-13.
33. Chin M, Goldman L. Correlates of early hospital readmission or death in patients with congestive heart failure. Am J Cardiol 1997; 79:1640-4.
34. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 2000; 36:453-71.
35. Gabriel SE, Crowson CS, O'Fallon WM. A comparison of two comorbidity instruments in arthritis. J Clin Epidemiol 1999; 52:1137-42.
36. Davies S, Russell L, Bryan J, Phillips L, Russell G. Comorbidity, urea kinetics and appetite in continuous ambulatory peritoneal dialysis patients: their interrelationship and prediction of survival. Am J Kidney Dis 1995; 26: 353-61.
37. Davies S, Phillips L, Naish P, Russell G. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 2002; 17:1085-92.
38. Jager K, Merkus M, Dekker F, Els W, Tijssen J, Stevens P, et al. Mortality and technique failurein patients starting chronic peritoneal dialysis treatment: results of the Netherlands Cooperative Study on The Adequacy of Dialysis. Kidney Int 1999; 55:1476-85.
39. Wright L. Survival in patients with end-stage renal disease. Am J Kidney Dis 1991; 17:25-8.
40. Greenfield S, Blanco DM, Elashoff RM, Aronow HU. Development and testing of a new index of comorbidity [Abstract]. Clin Res 1987; 35:346A.
41. Miskulin D, Athienites N, Yan G, Martin A, Ornt D, Kusek J, et al. Comorbidity assessment using the Index of Coexistent Diseases (ICED) in a multicenter clinical trial: the Hemodialysis (HEMO) Study. Kidney Int 2001; 60:1498-510.
42. Levey AS, Martin AA, Miskulin DC, Athienites NV, Meyer KB. Comorbidity assessment in ESRD: methods and results in a national dialysis chain [Abstract]. J Am Soc Nephrol 1999; 10:171(A).
43. Miskulin D, Meyer K, Martin A, Fink N, Coresh J, Powe N, et al. Baseline comorbidity and its change predict survival in an incident dialysis population. Am J Kidney Dis 2003; 41:149-61.
44. McClellan W, Anson D, Birkeli K, Tuttle E. Functional status and quality of life: predictors of early mortality among patients entering treatment for end-stage renal disease. J Clin Epidemiol 1991; 44:83-9.
45. Miskulin DC, Meyer KB, Athienites NV, Martin AA, Marsh JV, Fink NF, et al. The contribution of medical conditions and physical impairments to a comorbidity index: the Index of Coexistent Disease (ICED) [Abstract]. J Am Soc Nephrol 1999; 10:175(A).
46. Chanda S, Schulz J, Lawrence C, Greenwood R, Farrington K. Is there a rationale for rationing chronic dialysis? A hospital based cohort study of factors affecting survival and morbidity. Br Med J 1999; 318:217-23.
47. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1983; 143:29-36.
48. Miskulin D, Martin A, Brown R, Fink N, Coresh J, Powe N, et al. Predicting one-year mortality in an outpatient hemodialysis population: a comparison of comorbidity instruments. Nephrol Dial Transplant 2004; 19:413-20.
49. Cook D. Performance of the APACHE III models in an Australian ICU. Chest 2000; 118:1732-8.
50. Knaus W, Wagner D, Draper E, Zimmerman J, Bergner M, Bastos R et al. The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100:1619-36.
51. Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Prodzinski J, McDonell M, et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol 1995; 25:333-41.
52. Greenfield S, Sullivan L, Dukes KA, Silliman R, D'Agostino R, Kaplan SH. Development and testing of a new measure of case mix for use in office practice. Med Care 1995; 33 (4 Suppl):AS47-AS55.
53. DeOreo PB. Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-associated compliance. Am J Kidney Dis 1997; 30:204-12.
54. Mapes D, Lopes A, Satayathum S, McCullough K, Goodkin D, Locatelli F, et al. Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 2003; 64:339-49.
55. Zager P, Nikolic J, Brown R, Campbell M, Hunt W, Peterson D, et al. "U" curve association of blood pressure and mortality in hemodialysis patients. Kidney Int 1998; 54:561-9.
56. Fleischmann E, Teal N, Dudley J, May W, Bower J, Salahudeen A. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int 1999; 55:1560-7.
57. Leavey S, Strawderman R, Jones C, Port F, Held P. Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Dis 1998; 31: 997-1006.
58. Block G, Hulbert-Shearon T, Levin N, Port F. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31:604-17.
59. Kalantar-Zadeh K, Kopple J, Block G, Humphreys M. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2001; 38:1251-63.
60. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis. Kidney Int 1999; 55:648-58.
61. Myers G, Rifai N, Russell P, Roberts W, Alexander R, Biasucci L, et al. CDC/AHA workshop on markers of inflammation and cardiovascular disease. Circulation 2004; 110:e545-9.
62. Miskulin D, Coresh J, Klag M, Levin N, Fink N, Powe N, et al. Can serum CRP and IL-6 levels replace comorbidity in predicting mortality in dialysis patients [Abstract]? J Am Soc Nephrol 2004; 15:382A.
63. Elwood M. Critical Appraisal of Epidemiological Studies and Clinical Trials. 2nd ed. New York, NY: Oxford; 1998.
64. Greene T, Beck GJ, Gassman JJ, Gotch FA, Kusek JW, Levey AS, et al. Design and statistical issues of the Hemodialysis (HEMO) Study. Control Clin Trials 2000; 21:502-25.
65. Liu Y, Coresh J, Eustace J, Longenecker J, Jaar B, Fink N, et al. Association between cholesterol level and mortality in dialysis patients. JAMA 2004; 291:451-9.
66. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15:458-82.
67. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002; 62: 1887-93.
68. Coresh J, Longenecker J, Miller E. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 1998; 9(Suppl 1):S24-30.
69. Kalantar-Zadeh K, Block F, Humphreys M, Kopple J. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63:793-808.
70. Fleischmann E, Bower J, Salahudeen A. Risk factor paradox in hemodialysis: better nutrition as a partial explanation. ASAIO J 2001; 47:74-81.
71. Leavey SF, McCullough K, Hecking E, Goodkin D, Port F, Young E. Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2001; 16:2386-94.
72. Stack A, Molony D, Rahman N, Dosekun A, Murthy B. Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States. Kidney Int 2003; 64:1071-9.
73. Stack A, Murthy B, Molony D. Survival differences between peritoneal dialysis and hemodialysis among "Large" ESRD patients in the United States. Kidney Int 2004; 65: 2398-408.
74. Centers for Medicare & Medicaid Services. 2001 ESRD Clinical Performance Measures Project. Am J Kidney Dis 2002; 39(5 Suppl 3):S1-98.
75. Greenfield S, Nelson EC, Zubkoff M, Manning W, Rogers W, Kravitz RL, et al. Variations in resource utilization among medical specialties and systems of care. JAMA 1992; 267: 1624-30.
76. Lacson Jr E, Teng M, Lazarus J, Lew N, Lowrie E, Owen W. Limitations of the facility-specific standardization mortality ratio for profiling health care quality in dialysis units. Am J Kidney Dis 2001; 37:267-75.
77. Chertow GM. Leveling the "paying" field in end-stage renal disease. Am J Med 2000; 108:666-8.
78. Tonelli M, Gill J, Pandeya S, Bohm C, Levin A, Kiberd B. Barriers to blood pressure control and angiotensin enzyme inhibitor use in Canadian patients with chronic renal insufficiency. Nephrol Dial Transplant 2002; 17:1426-33.
79. Manley H, Garvin C, Drayer D, Reid G, Bender W, Neufeld T, et al. Medication prescribing patterns in ambulatory hemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider. Nephrol Dial Transplant 2004; 19:1842-8.
80. National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Transplant 2004; 4(Suppl 7):7-53.
81. Nissenson A, Collins J, Dickmeyer J, Litchfield T, Mattern W, McMahill C, et al. Evaluation of disease-state management of dialysis patients. Am J Kidney Dis 2001; 37: 938-44.
82. Manley H, Drayer D, Muther R, Hebbar S, Miskulin D. Impact of multidisciplinary team on cardiovascular risk (CV) reduction in hemodialysis (HD) patients: Dialysis Risk Factor Intervention Trial [Abstract]. J Am Soc Nephrol 2004; 15:191A.
83. Manley H, Drayer D. Clinical pharmacy interventions reduce ambulatory hemodialysis (HD) patients cardiovascular risk [Abstract]. J Am Soc Nephrol 2004; 153A.